Clinical trials can be a lifeline for patients with cancer, providing leading-edge care by clinicians dedicated to a specific disease, and the oncology community is filled with stories of patients whose lives were improved and/or extended due to participation in a trial. Despite the potential of clinical research to improve outcomes for patients with cancer, enrollment in trials remains stubbornly low—fewer than 3% of cancer patients in the U.S. participate.1According to a review of 7,776 adult oncology trials between 2005 and 2011, 20% closed early due to failure to meet their enrollment targets.2
1Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington (DC): National Academies Press (US); 2010.
2Stensland KD, et al. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic? JNCI. September 2014;106(9). https://doi.org/10.1093/jnci/dju229.
ACCC is committed to increasing the clinical trials “footprint” within community oncology. In Phase 1 of this project, ACCC will reach out to multidisciplinary cancer care team members to develop specific resources to help raise awareness and increase foundational knowledge around clinical research.
This monthly online newsletter highlights promising new trials and offers expert guidance in clinical trial access and operations to help community oncology close the gap on cancer research.
Key results from a recent nationwide survey on the role of APs in cancer clinical research. (November 2, 2020)
Learn more about resources which already exist, successful models for pharmacist integration into oncology research teams, and the unique skills which pharmacists offer the interdisciplinary team.
Join Nadine J. Barrett as she details strategies to improve clinical trial accrual for racial and ethnic minorities, as well as other at-risk groups. (July 24, 2020)
ACCC President Randall A. Oyer, MD, Medical Director, Oncology Program, Penn Medicine Lancaster General Health, discusses the landscape of oncology clinical trials during the COVID-19 pandemic, includes Q&A. (April 3, 2020)
Learn about the importance of reaching diverse populations with clinical trials where they live and how one clinical trial has prioritized community engagement.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Learn how a rural health system harnessed its passion and creativity to work around obstacles to clinical trial access and ensure its patients have access to cutting-edge cancer treatments.